KYP 2047

Product Description

KYP 2047 is a high affinity prolyl oligopeptidase (POP) inhibitor (K_i = 0.023 nM). Clears α-synuclein aggregates induced by oxidative stress in neuronal cells. Inhibits the formation of AcSDKP from its precursor 43-mer thymosin β4 (Tβ4). Induces angiogenesis via POP inhibition. It reduces tau aggregation in tau-transfected HEK-293 cells and N2A cells as well as in human iPSC-derived neurons from patients with frontotemporal dementia. In vivo, treatment with KYP 2047 of transgenic mice with tauopathy, reduces tau aggregation in the brain and cerebrospinal fluid and slows cognitive decline. Anti-angiogenic and neuroprotective. Brain penetrant.

Solubility

Preparing Stock Solutions for KYP 2047

The following data is based on the product molecular weight 339.44

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.95 mL	14.73 mL	29.46 mL
5 mM	0.59 mL	2.95 mL	5.89 mL
10 mM	0.29 mL	1.47 mL	2.95 mL
50 mM	0.06 mL	0.29 mL	0.59 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Eteläinen A prolyl oligopeptidase inhibitor reduces tau pathology in cellular models and in mice with tauopathy. Sci.Transl.Med. 2023 PMID: 37043557
• Venäläinen Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors. Biochem.Pharmacol. 2006 PMID: 16405869
• Myöhänen Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner. Br.J.Pharmacol. 2011 PMID: 21133893
• Jalkanen Brain pharmacokinetics of two prolyl oligopeptidase inhibitors, JTP-4819 and KYP-2047, in the rat. Basic Clin.Pharmacol.Toxicol. 2011 PMID: 21707925
• Myöhänen A prolyl oligopeptidase inhibitor, KYP-2047, reduces alpha-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease. Br.J.Pharmacol. 2012 PMID: 22233220
• Yedlapudi Inhibition of alpha-synuclein aggregation by multifunctional Da agonists assessed by a novel in vitro assay and an in vivo Drosophila synucleinopathy model. Sci Rep. 2016 PMID: 27917933